课题基金 / 基金详情

A novel use of E2f and Cdk inhibitors to prevent RB1-null tumors in genetically engineered models of retinoblastoma and other cancers

A novel use of E2f and Cdk inhibitors to prevent RB1-null tumors in genetically engineered models of retinoblastoma and other cancers
E2f 和 Cdk 抑制剂在视网膜母细胞瘤和其他癌症基因工程模型中预防 RB1 缺失肿瘤的新用途
批准号：
274466
负责人：
McCurdy Sean
金额：
$10.93万
依托单位：
University of Toronto
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2012
资助国家：
加拿大
项目状态：
已结题
起止时间：
2012-11-01 至 2015-11-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=274466&lang=en
关键词：
Cancer Therapy Cell Cycle Chemoprevention Conditional Knockouts Drug Delivery In Vivo Imaging Neurogenesis Translational Research Tumorigenesis

项目摘要

项目成果

McCurdy Sean的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cancer is a multi-step process, consisting of initiation and transformation phase. During initiation, there is continuous and progressive selection for aggressive clones by acquiring mutations. Apart from mutations in oncogenes and tumor-suppressor, we k
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigation of RNAi strategies to treat Retinoblastoma and other ocular diseases
  • 批准号：
    200987
  • 项目类别：
    Studentship Programs
  • 资助金额：
    $1.27万
  • 财政年份：
    2010
  • 负责人：
    McCurdy Sean
  • 依托单位：
    Toronto Western Hospital
海外基金